Andrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $88.78, for a total value of $710,240.00. Following the transaction, the chief financial officer now owns 109,491 shares of the company’s stock, valued at $9,720,610.98. This trade represents a 6.81 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Andrew Guggenhime also recently made the following trade(s):

• On Friday, October 18th, Andrew Guggenhime sold 42,000 shares of Vaxcyte stock. The shares were sold at an average price of $115.39, for a total transaction of $4,846,380.00.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $86.53 on Friday. The business has a 50-day simple moving average of $98.70 and a 200 day simple moving average of $92.13. The firm has a market capitalization of $10.78 billion, a price-to-earnings ratio of -18.81 and a beta of 0.94. Vaxcyte, Inc. has a one year low of $53.83 and a one year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same period last year, the business earned ($0.91) EPS. On average, sell-side analysts expect that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Bank of America upped their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Leerink Partners lifted their price objective on Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 3rd. Mizuho upped their target price on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $145.71.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in PCVX. Janus Henderson Group PLC raised its holdings in shares of Vaxcyte by 23.1% in the 3rd quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock worth $1,247,954,000 after acquiring an additional 2,052,989 shares during the last quarter. RA Capital Management L.P. raised its stake in shares of Vaxcyte by 5.9% in the third quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock worth $992,914,000 after purchasing an additional 485,436 shares during the last quarter. State Street Corp raised its stake in shares of Vaxcyte by 1.1% in the third quarter. State Street Corp now owns 3,405,743 shares of the company’s stock worth $389,174,000 after purchasing an additional 38,596 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Vaxcyte by 13.2% in the third quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company’s stock valued at $315,162,000 after purchasing an additional 324,560 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Vaxcyte by 10.6% during the third quarter. Geode Capital Management LLC now owns 2,700,782 shares of the company’s stock valued at $308,675,000 after buying an additional 259,010 shares during the last quarter. 96.78% of the stock is owned by institutional investors.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.